- Home
- JQC vs GHRS Comparison
JQC vs GHRS Comparison
Compare JQC & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JQC
- GHRS
- Stock Information
- Founded
- JQC 2003
- GHRS 2018
- Country
- JQC United States
- GHRS Ireland
- Employees
- JQC N/A
- GHRS N/A
- Industry
- JQC Finance Companies
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- JQC Finance
- GHRS Health Care
- Exchange
- JQC Nasdaq
- GHRS Nasdaq
- Market Cap
- JQC 752.6M
- GHRS 811.3M
- IPO Year
- JQC N/A
- GHRS 2021
- Fundamental
- Price
- JQC $5.52
- GHRS $13.50
- Analyst Decision
- JQC
- GHRS Strong Buy
- Analyst Count
- JQC 0
- GHRS 8
- Target Price
- JQC N/A
- GHRS $30.63
- AVG Volume (30 Days)
- JQC 714.6K
- GHRS 245.9K
- Earning Date
- JQC 01-01-0001
- GHRS 08-07-2025
- Dividend Yield
- JQC 11.13%
- GHRS N/A
- EPS Growth
- JQC N/A
- GHRS N/A
- EPS
- JQC N/A
- GHRS N/A
- Revenue
- JQC N/A
- GHRS N/A
- Revenue This Year
- JQC N/A
- GHRS N/A
- Revenue Next Year
- JQC N/A
- GHRS N/A
- P/E Ratio
- JQC N/A
- GHRS N/A
- Revenue Growth
- JQC N/A
- GHRS N/A
- 52 Week Low
- JQC $4.82
- GHRS $6.00
- 52 Week High
- JQC $5.65
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- JQC 48.56
- GHRS 51.16
- Support Level
- JQC $5.49
- GHRS $12.79
- Resistance Level
- JQC $5.58
- GHRS $14.35
- Average True Range (ATR)
- JQC 0.04
- GHRS 0.69
- MACD
- JQC -0.00
- GHRS 0.17
- Stochastic Oscillator
- JQC 30.77
- GHRS 66.67
About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.